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Abstract
Background: Various effects on pain have been reported with respect to their statistical significance, but a standardized
measure of effect size has been rarely added. Such a measure would ease comparison of the magnitude of the effects across
studies, for example the effect of gender on heat pain with the effect of a genetic variant on pressure pain.
Methodology/Principal Findings: Effect sizes on pain thresholds to stimuli consisting of heat, cold, blunt pressure,
punctuate pressure and electrical current, administered to 125 subjects, were analyzed for 29 common variants in eight
human genes reportedly modulating pain, gender and sensitization procedures using capsaicin or menthol. The
genotype explained 0–5.9% of the total interindividual variance in pain thresholds to various stimuli and produced
mainly small effects (Cohen’s d 0–1.8). The largest effect had the TRPA1 rs13255063T/rs11988795G haplotype explaining
.5% of the variance in electrical pain thresholds and conferring lower pain sensitivity to homozygous carriers. Gender
produced larger effect sizes than most variant alleles (1–14.8% explained variance, Cohen’s d 0.2–0.8), with higher pain
sensitivity in women than in men. Sensitization by capsaicin or menthol explained up to 63% of the total variance (4.7–
62.8%) and produced largest effects according to Cohen’s d (0.4–2.6), especially heat sensitization by capsaicin (Cohen’s
d=2.6).
Conclusions: Sensitization, gender and genetic variants produce effects on pain in the mentioned order of effect sizes. The
present report may provide a basis for comparative discussions of factors influencing pain.
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Introduction
Pain is a complex and multi-factorial [1] trait and influenced by
various and heterogeneous factors such as gender [2], genetic [3]
or environmental causes [4]. Individual differences in pain
responses [5] have been employed as a research tool of nociceptive
or nocifensive mechanisms and are contemplated as a basis for
personalized therapy approaches to pain. The multitude of factors
modulating pain suggests a comparative assessment of their
influences.
However, an experiment has a statistically significant effect, but
also the size of any observed effects. In practical situations, effect
sizes are helpful for making decisions. Although various effects on
pain have been reported with respect to their statistical
significance, a standardized measure of effect size has been rarely
added. Such a measure would ease comparison of the magnitude
of the effects across studies, for example the effect of gender on
experimental heat pain with the effect of a genetic variant on
pressure pain or clinical pain estimates. Reporting effect sizes is
considered good practice when presenting empirical research
findings in many fields [6]. In the present analysis, the effect sizes
of factors currently of interest as modulators of pain, i.e., common
genetic variants reportedly modulating pain (Table 1), gender
[2,7,8] and sensitization procedures by capsaicin [9] or menthol
[10] are provided.
Methods
Subjects and design
The study was conducted following the Declaration of Helsinki
on Biomedical Research Involving Human Subjects. The
University of Frankfurt Medical Faculty Ethics Review Board
approved the study protocol. Informed written consent was
obtained from all subjects. Pain thresholds to various experimen-
tal stimuli had been determined during previous assessments
[11,12] in a random sample of 125 unrelated healthy caucasian
volunteers (69 men, 56 women, aged 18 to 46 years, mean
2564.4 years). Exclusion criteria were drug intake dated back less
than a week except for oral anticonceptionals, an actual clinical
condition involving pain, and actual diseases according to
questioning and medical examination. A training session was
performed prior to the actual experiments, however, without
application of sensitization procedures. Employing an open non-
randomized design the actual measurements (for pain models, see
the following section) took place in the order cold pain, menthol
application, von Frey hair pain, cold/menthol pain, heat pain,
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17724Table 1. Effect sizes, expressed as percentage of the total variance explained by the genetic factors, on pain thresholds.
Factor
Polymorphism
(dbSNP database number) Ref. MAF [%]
Effect sizes on pain thresholds (percentage explained
variance of total variance), recessive hereditary model
Genotype Von Frey Heat Cold
Blunt
pressure Electric
OPRM1
(m-opioid receptor)
rs1799971 A.G [28,50] 9.2 0.35 0.76 0.08 1.74 1.43
OPRD1
(d-opioid receptor)
rs1042114 T.G [29] 17.2 0.04 0.2 0.45 2.02 4.74
rs2234918 T.C [29] 44.4 0.25 0.79 0.04 1.14 0
COMT (Cathechol-
O-methyl transferase)
rs4646312 T.C [30] 36.8 1.08 0.77 0.47 0.44 0.04
rs6269 A.G [30] 37.6 0.77 1.45 0.01 0 0.21
rs4633 C.T [51] 54 2.33 0.2 0.32 1.16 1.17
rs4680 G.A [52,53] 53.2 0.99 0.41 0.29 0.62 1.17
rs6269G/rs4633C/4818G/rs4680G [51] 36.4 0.77 1.45 0.01 0 0.21
rs6269A/rs4633T/4818C/rs4680A 50.8 0.6 1.05 1.2 0.71 1.9
rs6269A/rs4633C/4818C/rs4680G 8.4 - - - - -
rs4646312T/rs165722T/rs6269A/
rs4633T/rs4818C/rs4680A
[30] 49.6 1.08 1.28 0.55 0.18 1.41
rs4646312C/rs165722C/rs6269G/
rs4633C/rs4818G/rs4680G
34 0.51 0.5 0.03 0.08 0.23
rs4646312T/rs165722C/rs6269A/
rs4633C/rs4818C/rs4680G
7.6 - - - - -
TRPV1 (Transient
receptor potential
cation channel,
subfamily V, member 1)
rs8065080 A.G [29] 36.8 0.27 0.18 0.01 0.04 0.11
TRPA1 (Transient
receptor potential
cation channel,
subfamily A, member 1)
rs11988795 G.A [30] 32.8 1.02 0.06 0.26 0.01 0.26
rs13255063A/rs11988795G [30] 38.8 0.1 0.06 1.42 0.26 0.01
rs13255063A/rs11988795A 32.8 1.02 0.06 0.26 0.01 0.26
rs13255063T/rs11988795G 28.4 3.49 0.92 3.74 0.25 5.91
FAAH (Fatty acid
amide hydrolase)
rs932816 G.A [30] 23.6 0.03 0.06 0.06 1.26 0.56
rs4141964 T.C [30] 42.8 0.17 0.12 0.05 0.5 0.11
rs2295633 G.A [30] 41.6 0.47 0.32 0.02 0.09 0.01
rs932816G/rs4141964T 34.4 1.37 1.31 0.81 0.08 0.26
rs932816G/rs4141964C 42 0.04 0.31 0.03 0.01 0.11
rs932816A/rs4141964T 22.8 0.03 0.06 0.06 1.26 0.56
rs324419C/rs2295633G 58.4 0 0.13 0.01 1.2 0.58
rs324419C/rs2295633A 22.4 0.01 0.12 0.27 0.2 0.33
rs324419T/rs2295633A 19.2 1.3 0.14 0.99 0.72 0.99
GCH1 (GTP
cyclohydrolase 1)
1 particular haplotype of 3
SNPs associated to one of 15 SNPs
[41,42] 16.4 1.08 1.6 0.89 0.45 0.63
MC1R
(Melanocortin-1
receptor)
2 variant alleles of 29insA,
451C.T, 478C.T, 479G.A, 880G.C
(‘‘red head fair skin’’ phenotype, n=2)
[54] 451T: 6.4%,
478T: 6%,
others: 0–0.4%
0.01 1.09 0.47 0 0
#MAF: Observed minor allelic frequencies. ‘‘Minor’’ refers to the allele reported to be minor in gene databases. When its reported allelic frequency is close to 50%, it can
happen that the ‘‘minor’’ allele has a frequency .50% in the actual cohort. We nevertheless preserved the denomination ‘‘minor’’ to be consistent with SNP databases.
The reference and the observed allelic frequencies are given, and the recessive hereditary model was used, i.e., assigning heterozygous subjects to the group of
homozygous mutated carriers. The effect sizes are given in italic letters when they were larger than those of gender, and in bold letters when exceeding, arbitrarily
chosen, 5%.
doi:10.1371/journal.pone.0017724.t001
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pressure pain and von Frey hair/capsaicin pain, at intervals of
3–5 min between models.
Assessment of pain
The study assessed pain thresholds to various stimuli defined as
‘‘the least experience of pain which a subject can recognize’’
(http://www.iasp-pain.org). Pain models were applied without
knowledge of the genotypes. Five different stimuli were applied to
include a broad variety of thermal, mechanical and electrical pain
[11,12]. In brief, heat stimuli were applied using a 363c m
thermode (Thermal Sensory Analyzer, Medoc Advanced Medical
Systems Ltd., Ramat Yishai, Israel) placed onto the skin of the left
volar forearm. Its temperature was increased from 32uC by 0.3uC/s
until the subject pressed a button at the first sensation of pain, which
triggered cooling of the thermode by approximately 1.2uC/s. Heat
stimuli wereapplied eight times at random intervals of 25–35 s. The
median of the last five responses was defined as the heat pain
threshold because in previous experiments a plateau was reached
after the first three measurements. Cold stimuli were applied at
innersideoftherightforearm,similarlytoheatpainthresholds.The
temperaturewas decreasedfrom32uCto0 uCby1uC/s.Asprevious
experiments had shown that measurements are stable from the first
application, five repetitions were used and the threshold was the
median of these measurements. Blunt pressure was exerted
perpendicularly onto the dorsal side of mid-phalanx of the right
middle finger using a pressure algometer with a circular and flat
probe of 1 cm diameter (JTECH Medical, Midvale, USA). The
pressure was increased at a rate of approximately 9 N/cm
2 per
second until the subject reported pain. The procedure was repeated
five times at intervals of 30 s. Mechanical pain threshold to blunt
pressure was the median of the five measurements. Punctate
pressure was exerted onto the left volar forearm using von Frey
hairs (0.008, 0.02, 0.04, 0.07, 0.16, 0.4, 0.6, 1, 1.4, 2, 4, 6, 8, 10, 15,
26, 60, 100, 180, 300 g; North Coast Medical Inc., Morgan Hill,
CA, USA). Von Frey hairs were applied at randomized order
and the pain threshold was the (log-transformed) turning point at
50% probability of a logistic regression of the ‘‘pain/no-pain’’
answers. During the experiments, subjects had to keep their eyes
closed to avoid recognition of the von Frey hairs’ strength.
Electrical stimuli were applied using a constant current device
(NeurometerH CPT, Neurotron Inc., Baltimore, MD). It delivered
sine-wave stimuli at 5 Hz applied via two gold electrodes placed
on the medial and lateral side of the mid-phalanx of the right
middle finger. Their intensity was increased from 0 to 20 mA
by 0.2 mA/s until the subjects interrupted the current by releasing
a button. Measurements were repeated five times at intervals of 30 s
and the median of these measurements was submitted to statistics
as the electrical pain threshold. Sensitization was assessed
with punctate mechanical and heat [9] stimuli and obtained
using capsaicin cream (0.1 g, 0.1%, manufactured by the local
pharmacy) applied onto a 363 cm skin area on the left volar
forearm and covered with a plaster for 20 min. Sensitization to
cold stimuli [10] was assessed using menthol solution (2 ml of a
40% menthol solution dissolved in ethanol) applied in a soaked
plaster onto a 363 cm skin area on the right volar forearm
for 20 min.
Data analysis
To obtain the genotypes for this assessment, those single
nucleotide polymorphisms (SNP) or haplotypes reported until June
2008 to modulate experimental pain in healthy average people
(n=29, Table 1) were diagnosed by means of validated
Pyrosequencing
TM assays. Genotypes were submitted to further
analysis after verifying that the distribution of homozygous and
heterozygous carriers of variants was as expected from the Hardy-
Weinberg [13] law (x
2 goodness-of-fit tests: p.0.05).
The physical strengths of the stimuli at which the subjects’
answer to the question ‘‘Does it hurt?’’ changed from ‘‘No’’ to
‘‘Yes’’ were the pain threshold to the respective stimuli and were
analyzed for the effect sizes of the genetic and non-genetic factors.
The portion of the total variance in a pain threshold
explained by a particular factor was calculated for every factor
j (genetic variants including SNPs and in-silico obtained haplotypes
[14], gender or sensitization by capsaicin or menthol application)
as r2
j ~1{
SSerror
SStotal
, where SS denotes the sum of squared
deviations from the mean of the respective pain scores j, and the
error SS describes the SS being not due to the genetic or gender
factor. As sensitization involved repeated measurements, the
variance explained was assessed using a resampling procedure
without replacement that provided 1000 new data sets containing
either the non-sensitized or sensitized thresholds from a single
person, which allowed using sensitization as an inter-individual
factor as gender or genetics.
In meta-analysis often performed to draw standardized
information about effect sizes from heterogeneous data sets, the
effect sizes are being quantified by calculating Cohen’s d [15] as
a widely used standardized effect size measure appropriate to use
in the context of a t-test on means. Specifically, genotype effects
can be assessed by means of t-tests, i.e., in the dominant hereditary
model by comparing carriers with non-carriers of a variant, and in
the recessive hereditary model by comparing homozygous carriers
of a variant with pooled heterozygous and non-carriers. Stan-
dardized group differences in parameter means were calculated as
dj~
m1,j{m0,j ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n0,j{1
  
s2
0,jz n1,j{1
  
s2
1,j
n0,jzn1,j
s , where m0,j, m1,j and s0,j, s1,j
denote the means and standard deviations of the pain scores in the
carriers or non-carriers of the compared property j. The result is a
unit-free number of which, an absolute value of d=0.2 is regarded
as a small effect, 0.5 as a medium and .0.8 as a large effect [15].
Results
The original physical stimulus strengths at which the stimuli
became painful are shown in Figure 1 (left panels). The different
genotypes explained 0–5.9% (Table 1 and .Table 2) of the
variance in these pain thresholds to the different stimuli. For
example, the GCH1 haplotype explained 4% of the interindividual
variance in pressure pain thresholds while the d-opioid receptor
variant rs1042114 explained 2.5% of the variance across subjects
in von Frey hair thresholds. According to Cohen’s d (Table 3 and
Table 4), the genotype effect sizes had to be considered as mostly
small (range 0–1.78). A gene dose effect resulted in somewhat
larger effect sizes in homozygous carriers. However, only the
TRPA1 rs13255063T/rs11988795G haplotype explained .5% of
the variance, namely of that in electrical pain threshold.
Homozygous carriers had a higher pain threshold to electrical
stimuli (3.862 mA versus 2.561.2 mA, p=0.006).
Gender produced explained 1–14.75% of the variance in the
different pain thresholds (Cohen’s d 0.2–0.84). The comparatively
greatest fractions of the variance explained by gender were seen
for blunt pressure and electric stimuli. The gender effect was
directed toward higher pain sensitivity in women than in men.
Sensitization by capsaicin increased the pain thresholds to
heat and punctate pressure (Wilcoxon tests: p,0.001) whereas
menthol decreased the cold pain thresholds (Wilcoxon test:
Effects Sizes in Experimental Pain
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total variance and produced the larges effects observed in this data
according to Cohen’s d=2.6. Sensitizations by capsaicin or
menthol of punctate or cold pain explained 7.5 or 4.6% of the
variance in those thresholds and produced medium to small effect
sizes (Cohen’s d=0.53 and 0.4, respectively).
Discussion
Pain thresholds were subject to various influences, which was
most readily visible for capsaicin sensitization of heat pain
perception and to a smaller extend of menthol sensitization for
cold pain thresholds (Figure 1 last two lines). The basis of this large
effect on heat pain thresholds is the synergistic effects of the
excitations of TPRV1 by both, heat (.43uC) and capsaicin
[16,17]. As TRPV1 receptor potential channels are also
considered general nocisensors [18], the effect on punctate
mechanical pain has a similar explanation although the sensitiza-
tion had smaller effects than on heat pain. Analogously, the effect
of menthol sensitization on cold pain thresholds can be explained
by a concomitant excitation of TRPM8 by both, cold stimuli
between 8 and 28uC and menthol [19,20,21].
A part of the total variance in pain thresholds was accounted for
by the subject’s gender, exceeding 1/10 for blunt pressure and
electrical pain stimuli. Gender effects on pain have been
established for long and their present direction toward higher
pain sensitivity in women than in men agrees with most studies (for
reviews, see [2,7,8]). Explanations use sex hormones [22,23] or
differences in the function of the endogenous opioid system [24]
such as a sexual dimorphism regarding opioid receptor function in
rat brain structures mediating opioid analgesia [25]. Interaction of
sex and genetics may follow from sex differences in the functioning
of, e.g., m- and d-opioid receptors, COMT or FAAH [26]. Sex-
differences in the response to exogenous opioids in rats were
reported to depend on the genotype [27]. A sex by genotype
interaction emerged for heat pain ratings with respect to the
human OPRM1 118A.G polymorphism [28] and thermal pain
sensitivity was also modulated by gender, ethnicity and psycho-
logical factors [29].
Figure 1. Observed thresholds to different pain stimuli and
sizes of modulatory effects. Left part: Single values of the
measured pain thresholds to various stimuli are shown as dots, with
statistical summaries in overlaid box plots. The boxes span the 25
th to
75
th percentiles, with the median crossing the box as a horizontal line,
and the whiskers spanning values within 1.5 times the 25
th to 75
th
percentiles. The subject’s gender is indicated by different symbols and
colors (men: red circles, women: blue crosses). At the right of each
thresholds presentation, the effect sizes of the genetic variants
obtained using the dominant hereditary model (blue filled circles),
i.e., heterozygous and homozygous carriers of the variant alleles versus
wild type subjects, and the recessive model (red empty circles), i.e.,
homozygous carriers of the variant versus the other subjects, are shown
as correlation plots between the fraction of the total variance in the
respective threshold explained by the respective factor and Cohen’s d
of that factor. An absolute value of d=0.2 indicates a small effect,
values around 0.5 a medium and above 0.8 a large effect [15]. In
addition, the effects sizes of gender (green filled triangles) and
sensitization (orange filled squares) by capsaicin (heat, von Frey hair
punctate pressure) or menthol (cold) are shown. Note that the axis
scaling is non-uniform among panels to enhance data visibility. At the
bottom, the overall effect sizes (all Cohen’s d per condition genetics,
gender or sensitization) of all analyzed factors and stimuli are grouped
for genetic, gender and sensitization influences on pain thresholds,
showing decreasing sizes of effects in the order sensitization, gender
and genetics.
doi:10.1371/journal.pone.0017724.g001
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Factor
Polymorphism
(dbSNP database number)
Effect sizes on pain thresholds (percentage explained variance of total
variance), dominant hereditary model
Genotype Von Frey Heat Cold
Blunt
pressure Electric
OPRM1 (m-opioid
receptor)
rs1799971 A.G 0.21 0.56 0.28 0.2 0.14
OPRD1 (d-opioid
receptor)
rs1042114 T.G 2.47 0.01 1.17 0.12 0.58
rs2234918 T.C 0.76 0.72 0.76 0.13 0.06
COMT (Cathechol-O-
methyl transferase)
rs4646312 T.C 0.4 0.06 0.34 0.1 0.18
rs6269 A.G 0 0.86 3.5 1.47 1.53
rs4633 C.T 0.94 1.23 0.09 0.15 0.01
rs4680 G.A 1.83 0.46 0.02 0.03 0.12
rs6269G/rs4633C/4818G/rs4680G 0.13 0.14 1.52 0.87 0.52
rs6269A/rs4633T/4818C/rs4680A 1.4 0.71 0.12 0.02 0.01
rs6269A/rs4633C/4818C/rs4680G 3.93 0 1.47 0 0.48
rs4646312T/rs165722T/rs6269A/
rs4633T/rs4818C/rs4680A
1.51 0.65 0.01 0.02 0.03
rs4646312C/rs165722C/rs6269G/
rs4633C/rs4818G/rs4680G
0.04 0 1.09 0.51 0.5
rs4646312T/rs165722C/rs6269A/
rs4633C/rs4818C/rs4680G
4.47 0.12 1.3 0.03 0.57
TRPV1 (Transient receptor
potential cation channel,
subfamily V,
member 1)
rs8065080 A.G 0.03 0.85 0.29 0.63 1.37
TRPA1 (Transient receptor
potential cation channel,
subfamily A, member 1)
rs11988795 G.A 0.01 0.12 0.25 0.25 1.06
rs13255063A/rs11988795G 0.1 0.25 0.22 0.31 0.93
rs13255063A/rs11988795A 0.01 0.12 0.25 0.25 1.06
rs13255063T/rs11988795G 0.84 0.12 0.2 0.01 0.1
FAAH (Fatty acid
amide hydrolase)
rs932816 G.A 2.7 0.27 1.09 0.09 0.15
rs4141964 T.C 0.02 0.27 0 1.06 0.62
rs2295633 G.A 0 0.13 0.01 1.2 0.58
rs932816G/rs4141964T 0.51 0.7 0.48 0.28 0.01
rs932816G/rs4141964C 0.02 0.27 0 1.06 0.62
rs932816A/rs4141964T 3.38 0.47 1.03 0.05 0.15
rs324419C/rs2295633G 0.47 0.32 0.02 0.09 0.01
rs324419C/rs2295633A 0.08 0.04 1.62 0.34 0.39
rs324419T/rs2295633A 0.02 0.74 1.16 0.96 0.58
GCH1
(GTP cyclohydrolase 1)
1 particular haplotype of 3 SNPs
associated to one of 15 SNPs
0.38 0.3 0.35 3.97 0
MC1R (Melanocortin-
1 receptor)
2 variant alleles of 29insA, 451C.T,
478C.T, 479G.A, 880G.C
(‘‘red head fair skin’’ phenotype, n=2)
Gender 5.87 0.95 1.3 14.75 10.27
Sensitization 7.46 62.6 4.63
#MAF: Observed minor allelic frequencies. ‘‘Minor’’ refers to the allele reported to be minor in gene databases. When its reported allelic frequency is close to 50%, it can
happen that the ‘‘minor’’ allele has a frequency .50% in the actual cohort. We nevertheless preserved the denomination ‘‘minor’’ to be consistent with SNP databases.
In the case of the genetic factors, the reference and the observed allelic frequencies are given, and the dominant hereditary model was used, i.e., assigning
heterozygous subjects to the group of wild-type carriers. The effect sizes are given in italic letters when they were larger than those of gender, and in bold letters when
exceeding, arbitrarily chosen, 5%.
doi:10.1371/journal.pone.0017724.t002
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variance in pain thresholds. The effect sizes agreed with few
elsewhere reported effect sizes such as those of variants in COMT
or FAAH explaining 5–8% of the variance in experimental pain
measures [30], or that of OPRM1 rs1799971 of approximately
Cohen’s d=0.3 for heat and ischemic pain thresholds or tolerance
[28]. The largest genetic effect size in the present data was seen for
homozygous presence of the TRPA1 rs13255063T/rs11988795G
haplotype explaining .5% of the variance in electrical pain
thresholds. This genetic effect exceeded that of menthol
sensitization on cold stimuli. The cold-sensitive TRPA1 receptor
potential channel is mainly activated by noxious cold, chemical
Table 3. Effect sizes, expressed as absolute values of Cohen’s d [15], of the genetics factors on pain thresholds.
Factor
Polymorphism
(dbSNP database number) Effect sizes on pain thresholds (Cohen’s d), recessive hereditary model
Genotype Von Frey Heat Cold
Blunt
pressure Electric
OPRM1 (m-opioid
receptor)
rs1799971 A.G- - - - -
OPRD1 (d-opioid
receptor)
rs1042114 T.G 0.17 0.35 0.54 1.14 1.78
rs2234918 T.C 0.13 0.23 0.05 0.28 0.00
COMT (Cathechol-O-
methyl transferase)
rs4646312 T.C 0.30 0.26 0.20 0.19 0.06
rs6269 A.G 0.26 0.35 0.03 0.01 0.13
rs4633 C.T 0.34 0.10 0.12 0.24 0.24
rs4680 G.A 0.22 0.14 0.12 0.18 0.24
rs6269G/rs4633C/4818G/rs4680G 0.26 0.35 0.03 0.01 0.13
rs6269A/rs4633T/4818C/rs4680A 0.18 0.24 0.25 0.19 0.32
rs6269A/rs4633C/4818C/rs4680G - - - - -
rs4646312T/rs165722T/rs6269A/
rs4633T/rs4818C/rs4680A
0.24 0.27 0.17 0.10 0.28
rs4646312C/rs165722C/rs6269G/
rs4633C/rs4818G/rs4680G
0.23 0.23 0.06 0.09 0.15
rs4646312T/rs165722C/rs6269A/
rs4633C/rs4818C/rs4680G
-----
TRPV1 (Transient receptor
potential cation channel,
subfamily V, member 1)
rs8065080 A.G 0.16 0.13 0.03 0.06 0.10
TRPA1 (Transient receptor
potential cation channel,
subfamily A, member 1)
rs11988795 G.A 0.36 0.09 0.18 0.03 0.18
rs13255063A/rs11988795G 0.10 0.07 0.36 0.15 0.03
rs13255063A/rs11988795A 0.36 0.09 0.18 0.03 0.18
rs13255063T/rs11988795G 0.74 0.37 0.76 0.19 0.97
FAAH (Fatty acid
amide hydrolase)
rs932816 G.A 0.06 0.09 0.09 0.40 0.27
rs4141964 T.C 0.10 0.08 0.05 0.17 0.08
rs2295633 G.A 0.17 0.14 0.04 0.08 0.03
rs932816G/rs4141964T 0.37 0.36 0.28 0.08 0.16
rs932816G/rs4141964C 0.05 0.14 0.04 0.02 0.08
rs932816A/rs4141964T 0.06 0.09 0.09 0.40 0.27
rs324419C/rs2295633G 0.00 0.07 0.02 0.23 0.16
rs324419C/rs2295633A 0.06 0.28 0.41 0.35 0.46
rs324419T/rs2295633A 0.58 0.19 0.51 0.44 0.51
GCH1
(GTP cyclohydrolase 1)
1 particular haplotype of 3 SNPs
associated to one of 15 SNPs
0.6 0.72 0.54 0.38 0.45
MC1R
(Melanocortin-1 receptor)
2 variant alleles of 29insA, 451C.T,
478C.T, 479G.A, 880G.C
(‘‘red head fair skin’’ phenotype, n=2)
0.06 0.84 0.54 0.05 0.03
The recessive hereditary model was used, i.e., assigning heterozygous subjects to the group of homozygous mutated carriers. The effect sizes are given in italic letters
when they were larger than those of gender, and in bold letters when exceeding a value of 0.8 indicating a large effect.
doi:10.1371/journal.pone.0017724.t003
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time associated with TRPA1 rs1198795 had been observed in
another study [30]. A difficulty to explain the contrasting result
arises from lack of shown molecular consequences of the genetic
polymorphisms. As TRPA1 is a pain sensor [18], the results with
cold pain [30] point at an increased function associated with the
rs1198795 variant. Increased function is conveyed by another
TRPA1 mutation (N855S [32]) and associated with a rare
autosomal-dominant familial syndrome characterized by episodes
of debilitating upper body pain. However, the present observations
of decreased pain sensitivity in carriers of a TRPA1 haplotype, of
which rs1198795 is a part, point at a decreased function of TRPA1
Table 4. Effect sizes, expressed as absolute values of Cohen’s d [15], of the respective factor on pain thresholds.
Factor
Polymorphism
(dbSNP database number)
Effect sizes on pain thresholds (Cohen’s d), dominant genetic
model
Genotype Von Frey Heat Cold
Blunt
pressure Electric
OPRM1 (m-opioid receptor) rs1799971 A.G 0.12 0.20 0.14 0.12 0.10
OPRD1 (d-opioid receptor) rs1042114 T.G 0.34 0.02 0.23 0.07 0.16
rs2234918 T.C 0.19 0.19 0.19 0.08 0.06
COMT
(Cathechol-O-methyl transferase)
rs4646312 T.C 0.13 0.05 0.12 0.06 0.09
rs6269 A.G 0.01 0.19 0.39 0.25 0.26
rs4633 C.T 0.24 0.27 0.07 0.09 0.02
rs4680 G.A 0.34 0.17 0.04 0.04 0.08
rs6269G/rs4633C/4818G/rs4680G 0.07 0.08 0.25 0.19 0.15
rs6269A/rs4633T/4818C/rs4680A 0.28 0.20 0.08 0.03 0.02
rs6269A/rs4633C/4818C/rs4680G 0.54 0.01 0.33 0.00 0.19
rs4646312T/rs165722T/rs6269A/
rs4633T/rs4818C/rs4680A
0.29 0.19 0.02 0.03 0.04
rs4646312C/rs165722C/rs6269G/
rs4633C/rs4818G/rs4680G
0.04 0.00 0.21 0.15 0.14
rs4646312T/rs165722C/rs6269A/
rs4633C/rs4818C/rs4680G
0.60 0.10 0.32 0.05 0.21
TRPV1 (Transient receptor
potential cation channel,
subfamily V, member 1)
rs8065080 A.G 0.04 0.19 0.11 0.16 0.24
TRPA1 (Transient receptor
potential cation channel,
subfamily A, member 1)
rs11988795 G.A 0.02 0.07 0.10 0.10 0.21
rs13255063A/rs11988795G 0.07 0.10 0.10 0.12 0.20
rs13255063A/rs11988795A 0.02 0.07 0.10 0.10 0.21
rs13255063T/rs11988795G 0.18 0.07 0.09 0.02 0.06
FAAH
(Fatty acid amide hydrolase)
rs932816 G.A 0.34 0.11 0.22 0.06 0.08
rs4141964 T.C 0.03 0.11 0.00 0.22 0.17
rs2295633 G.A 0.0 0.07 0.02 0.23 0.16
rs932816G/rs4141964T 0.15 0.17 0.14 0.11 0.02
rs932816G/rs4141964C 0.03 0.11 0.00 0.22 0.17
rs932816A/rs4141964T 0.39 0.14 0.21 0.05 0.08
rs324419C/rs2295633G 0.17 0.14 0.04 0.08 0.03
rs324419C/rs2295633A 0.04 0.08 0.28 0.12 0.09
rs324419T/rs2295633A 0.02 0.14 0.26 0.21 0.2
GCH1
(GTP cyclohydrolase 1)
1 particular haplotype of 3 SNPs
associated to one of 15 SNPs
0.13 0.12 0.13 0.45 0.00
MC1R
(Melanocortin-1 receptor)
2 variant alleles of 29insA, 451C.T,
478C.T, 479G.A, 880G.C
(‘‘red head fair skin’’ phenotype, n=2)
-----
Gender 0.50 0.20 0.23 0.84 0.68
Sensitization 0.53 2.60 0.44
In the case of the genetic factors, the dominant hereditary model was used, i.e., assigning heterozygous subjects to the group of wild-type subjects. The effect sizes are
given in italic letters when they were larger than those of gender, and in bold letters when exceeding a value of 0.8 indicating a large effect.
doi:10.1371/journal.pone.0017724.t004
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few additional genetic variants modulating pain have not reached
the present set of genotypes. This relates to potassium ion channels
Kir3.2, for which the genetic variant KCNJ6 rs2070995 increased
opioid requirements [33,34], and Kv9.1 for which the genetic
KCNS1 variants rs734784 and rs13043825 were associated with
greater pain [35]. There is no strong indication that their inclusion
would have changed the picture of mostly small genetic effect sizes,
and information so far only shows a modulation of clinical pain
including neuropathic pain but not experimental pain. The latter
applies also to interleukin related genetic modulations of pain [36]
and other genetically polymorphic nociceptive factors [37].
Since pain is defined as ‘‘an unpleasant sensory and emotional
experience …’’ (International Association for the Study of Pain,
http://www.iasp-pain.org), it cannot be measured directly.
Correctly, the pain threshold is defined at a perceptional level as
the least experience of pain which a subject can recognize. In
contrast, the present pain threshold measures comprise the
physical intensities of the stimuli at which the subjects indicated
that they became painful. Therefore, the genetic factors, sex or
sensitization have in fact modulated the lowest stimulus’ strength
at which the subject indicated pain. The measurement of pain has
been addressed since more than half a century [38]. Quantitative
information about a subject’s pain may be obtained with several
other methods [39]. For example, subjects may indicate the
stimulus strength evoking unbearable pain (pain tolerance) or rate
their pain on nominal or analog scales. In search for an objective
quantification of pain, several surrogate measures have been
established, such as pain-related evoked cortical electrical
potentials, magnetic fields blood oxygen dependent signal, or
muscle reflexes [40].
The observed small effect sizes suggest that none of the tested
common factors suffices as a basis for clinical decisions or
prognostic judgments with respect to pain. This may be similar
for experimentally induced and clinical pain as the genetic effect of
some variants has been demonstrated in both. For example, the so-
called ‘‘pain-protective’’ GCH1 haplotype decreased pain in
healthy volunteers following administration of mechanical, heat
and ischemic pain [41] or the same pain models as presently used
[42], and it was associated with lower clinical pain following
surgical discectomy [41] and delayed development of pain from
the cancer diagnosis [43]. The poor effect size of common genetic
factors is reminiscent of other multigenetic traits such as body
height or type 2 diabetes, for which genome wide association
studies have mainly shown that the effects of single common
genetic variants on the phenotype are small [44]. This might a
major reason why genetics-based pain management advices have
not emerged in clinical practice [45,46], similar to gender
differences that have also raised expectations for individualized
therapies and have also not entered the clinical guidelines.
Therefore, an individualized pain therapy based on genotyping
information is not yet imminent.
This study did not intend to reproduce genetic associations but
to provide a basis for comparison of genetics’ effects on pain with
other effects across different studies and pain measurements.
Therefore, the report was limited to effect sizes, which have
become a standard part of reporting [47]. Standardized effects
sizes enhanced comparison across the pain stimuli and were
therefore preferred. However, if the units of measurement are
meaningful on a practical level, then reporting an unstandardized
measure has been advised [48]. In the present data, the difference
in the physical strength of each stimulus at which it evokes pain
has a practical meaning, i.e., N/m
2 for blunt pressure or mA of 5-
Hz electrical sine waves. However, the comparison across stimuli
is probably more meaningful when using standardized effect sizes.
This preserves the relative order of factors. However, standard-
izing loses the direction of the effect. The ‘‘canned’’ effect sizes
‘‘small’’, ‘‘medium’’, or ‘‘large’’ should not replace a decision
about how large a difference is that is based on understanding of
the experimental system [49].
On several pain stimuli, heat sensitization by capsaicin, gender
and genetic variants produced effects on pain in the mentioned
order of effect sizes (Figure 1 bottom). Reporting effect sizes is
considered good practice when presenting empirical research
findings in many fields and the present report may provide a basis
for comparative discussions of factors influencing pain.
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